Cannabis Use Disorder, Mental Health Disorder, Physical Illness
Conditions
Keywords
cannabis regulation, health effects, cannabis consumption
Brief summary
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.
Detailed description
This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.
Interventions
OTHERRegulated cannabis access in pharmacies
The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
Sponsors
Health Department of the Canton of Basel-Stadt
University of Basel
University Psychiatric Clinics Basel
Psychiatric Services Aargau AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Masking description
One group has immediately access to regulated cannabis access in pharmacies and the other group has to wait six months until they have regulated cannabis access.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly during the last 6 months (positive urine sample)
Exclusion criteria
* pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient psychiatric treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in problematic cannabis consumption behaviour | 6 / 12 /18 /24 / 30 months | Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in depression | 6 / 12 /18 /24 / 30 months | Patient Health Questionnaire; min. value 0, max. value 27; higher scores mean worse outcome |
| Change in anxiety | 6 / 12 /18 /24 / 30months | Generalized Anxiety Disorder; min. value 0, max. value 21; higher scores mean worse outcome |
| Change in psychosis | 6 / 12 /18 /24 / 30 months | Checklist of early intervention; min. value 0, max. value 8; higher scores mean worse outcome |
| Change in physical health | 6 / 12 /18 /24 / 30 months | Symptom Checklist - 90, Somatization; min. value 0, max. value 48; higher scores mean worse outcome |
Countries
Switzerland
Outcome results
None listed